Labcorp Closes $250M Acquisition of Empire City Laboratories Assets

Why It Matters

The acquisition deepens Labcorp’s foothold in the lucrative New York market and accelerates its growth strategy through integrated services and future hospital‑lab consolidations.

Key Takeaways

• Labcorp pays $165M upfront for Empire City assets
• Potential $85M additional milestones tied to performance
• Deal expands Labcorp’s New York patient service network
• Labcorp becomes integrated lab provider for Somos network
• M&A strategy aims to consolidate regional testing labs

Pulse Analysis

Labcorp’s closure of the Empire City deal marks a decisive step in its expansion across New York’s densely populated healthcare landscape. The $165 million upfront payment, supplemented by up to $85 million in milestone incentives, reflects the company’s willingness to invest heavily in strategic assets that can be quickly integrated into its existing platform. By acquiring patient service centers that already serve the Tri‑State area, Labcorp can immediately broaden its geographic reach while leveraging its extensive menu of routine and specialty tests, advanced data analytics, and digital health tools to enhance service quality.

The simultaneous multi‑year partnership with Somos amplifies the strategic value of the acquisition. Somos, a network caring for over one million New Yorkers, now designates Labcorp as its clinically integrated laboratory provider, granting Labcorp preferential access to a large, coordinated patient base. This alignment enables Labcorp to funnel specimens from Somos’ primary‑care and specialty practices through its expanded service centers, creating a seamless end‑to‑end testing experience. The integration also positions Labcorp to offer value‑added services such as real‑time results, predictive analytics, and tele‑health compatible reporting, differentiating it from regional competitors.

Labcorp’s New York moves are emblematic of a wider consolidation wave in the U.S. laboratory sector. Post‑pandemic pressures, evolving reimbursement models, and looming Medicaid uncertainties are prompting hospitals to seek stable, cost‑effective lab partners. CEO Adam Schechter’s emphasis on “accretive” deals that repay capital within two to three years underscores a disciplined financial approach. As Labcorp continues to close deals—13 in 2025 alone—it is building a national network capable of delivering economies of scale, improved bargaining power with payers, and a robust platform for future growth in an increasingly competitive diagnostics market.

Deal Summary

Labcorp announced the closing of its acquisition of assets from Empire City Laboratories, paying $165 million upfront with up to $85 million in milestone payments. The $250 million deal expands Labcorp’s patient service center network in New York and positions it as the integrated laboratory provider for Somos providers.